Skip to main content

Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy.

Publication ,  Journal Article
Karsdal, MA; Henriksen, K; Nielsen, MJ; Byrjalsen, I; Leeming, DJ; Gardner, S; Goodman, Z; Patel, K; Krag, A; Christiansen, C; Schuppan, D
Published in: Am J Physiol Gastrointest Liver Physiol
December 1, 2016

There are no approved treatments for liver fibrosis. To aid development of antifibrotic therapies, noninvasive biomarkers that can identify patients with progressive fibrosis and that permit monitoring of the response to antifibrotic therapy are much needed. Samples from a phase II antifibrotic trial of the glitazone farglitazar in patients with advanced hepatitis C, with matched follow-up liver biopsies, and from a phase III study of balaglitazone in patients with late-stage Type 2 diabetes (BALLET study) were analyzed for serological Pro-C3 levels in conjunction with other disease parameters. In the farglitazar study, a predefined cutoff value for Pro-C3 as a selection criterion led to the identification of subjects who 1) progressed by histological scores and 2) responded to therapy, as documented by attenuated fibrosis in liver biopsies. In the BALLET trial, subjects with the highest tertile of Pro-C3 levels responded to balaglitazone with reductions in levels of alanine aminotransferase and Pro-C3, as well as improved insulin sensitivity and lipid profile. Elevated Pro-C3 levels are indicative of active fibrogenesis and structural progression of fibrosis, and it can potentially identify patients most likely to benefit from antimetabolic and antifibrotic treatments. Serum Pro-C3 may facilitate patient selection and could help to speed up antifibrotic drug development and validation.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Physiol Gastrointest Liver Physiol

DOI

EISSN

1522-1547

Publication Date

December 1, 2016

Volume

311

Issue

6

Start / End Page

G1009 / G1017

Location

United States

Related Subject Headings

  • Tyrosine
  • Thiazolidinediones
  • Quinazolines
  • Patient Selection
  • Oxazoles
  • Middle Aged
  • Male
  • Liver Cirrhosis
  • Humans
  • Gastroenterology & Hepatology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Karsdal, M. A., Henriksen, K., Nielsen, M. J., Byrjalsen, I., Leeming, D. J., Gardner, S., … Schuppan, D. (2016). Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J Physiol Gastrointest Liver Physiol, 311(6), G1009–G1017. https://doi.org/10.1152/ajpgi.00283.2016
Karsdal, Morten A., Kim Henriksen, Mette Juul Nielsen, Inger Byrjalsen, Diana J. Leeming, Stephen Gardner, Zachary Goodman, et al. “Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy.Am J Physiol Gastrointest Liver Physiol 311, no. 6 (December 1, 2016): G1009–17. https://doi.org/10.1152/ajpgi.00283.2016.
Karsdal MA, Henriksen K, Nielsen MJ, Byrjalsen I, Leeming DJ, Gardner S, et al. Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J Physiol Gastrointest Liver Physiol. 2016 Dec 1;311(6):G1009–17.
Karsdal, Morten A., et al. “Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy.Am J Physiol Gastrointest Liver Physiol, vol. 311, no. 6, Dec. 2016, pp. G1009–17. Pubmed, doi:10.1152/ajpgi.00283.2016.
Karsdal MA, Henriksen K, Nielsen MJ, Byrjalsen I, Leeming DJ, Gardner S, Goodman Z, Patel K, Krag A, Christiansen C, Schuppan D. Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J Physiol Gastrointest Liver Physiol. 2016 Dec 1;311(6):G1009–G1017.

Published In

Am J Physiol Gastrointest Liver Physiol

DOI

EISSN

1522-1547

Publication Date

December 1, 2016

Volume

311

Issue

6

Start / End Page

G1009 / G1017

Location

United States

Related Subject Headings

  • Tyrosine
  • Thiazolidinediones
  • Quinazolines
  • Patient Selection
  • Oxazoles
  • Middle Aged
  • Male
  • Liver Cirrhosis
  • Humans
  • Gastroenterology & Hepatology